{
    "nctId": "NCT06085274",
    "briefTitle": "Sentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (SHINE)",
    "officialTitle": "Sentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (SHINE): A Prospective Clinical Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Non-inferiority of ICG SLNB compared to dual-tracer SLNB in post-neoadjuvant chemotherapy treated breast cancer patients.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adults \u2265 18 and \u2264 80\n2. Stage I-III core biopsy confirmed invasive breast cancer, who have undergone neoadjuvant chemotherapy and are planned to undergo SLNB with dual tracer (blue dye+Tc-99m)\n3. Eastern Cooperative Oncology Group (ECOG) \\< 2\n4. No ICG/iodine allergy\n5. Capable of providing informed consent\n6. English literacy\n\nExclusion Criteria:\n\n1. Significant medical comorbidities (ASA 4)\n2. Breast cancer stage T4/inflammatory or N2 disease at presentation (SLNB is contra-indicated in this setting)\n3. Clinical node positive after neoadjuvant therapy (SLNB is contra-indicated in this setting)\n4. Previous axillary surgery or breast/axillary radiotherapy to ipsilateral breast\n5. Active pregnancy or breastfeeding",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}